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Abstract 
Background: The replication of HBV involves the production of covalently closed circular DNA (cccDNA) from the 
HBV genome through the repair of virion relaxed circular DNA (rcDNA) in the virion. As cccDNA is the transcription 
template for HBV genomes, it needs to be eliminated from hepatocytes if the eradication of chronic HBV infection 
is to be achieved. PCR quantitation of cccDNA copy number is the technique of choice for evaluating the efficiency 
of treatment regimens. The PCR target commonly used to identify cccDNA spans the gapped region of rcDNA and 
is considered to accurately distinguish between cccDNA and rcDNA. There is however, a potentially confounding 
issue in that PCR can generate larger targets from collections of small DNA fragments, a phenomenon known as PCR 
recombination.
Results: The impact of PCR recombination towards the amplification of this cccDNA specific target was explored by 
mixing three marked, yet overlapping HBV DNA fragments. Thirteen of sixteen possible recombinants were identi‑
fied by sequencing with frequencies ranging from 0.6 to 23%. To confirm this finding in vivo, HBV positive sera were 
treated with DNase I and submitted to quantitative real‑time PCR. Under these conditions, it was possible to amplify 
the cccDNA specific segment without difficulty. As the virion contains uniquely rcDNA, amplification of the cccDNA 
target resulted from PCR recombination.
Conclusions: PCR quantitation of cccDNA may be more difficult than hitherto thought. Current detection protocols 
need to be investigated so as to help in the management of chronic HBV infection.
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Findings
Incoming partly double stranded hepatitis B virus (HBV) 
DNA genomes are completed by the viral polymerase 
generating relaxed circular DNA (rcDNA). Following 
translocation to the nucleus, the gaps are repaired by the 
host repair system to generate covalently closed circular 
DNA (cccDNA), the template for the HBV pregenome 
and viral mRNAs. Consequently, catabolism of cccDNA 
is necessary for the eradication of chronic HBV infection. 
cccDNA levels are a useful biomarker of HBV replica-
tion although its clinical use is restricted as it requires 
invasive sampling. PCR quantitation of cccDNA is widely 
used to assess the effectiveness of antiviral therapy or in 
the analysis of anti-HBV restriction factors [1–4].
As the amount of HBV rcDNA in the cell is much 
higher than cccDNA, distinguishing the latter is a chal-
lenge. The signal differences between the two forms 
are the two gaps in rcDNA. PCR across this region has 
been considered to selectively amplify cccDNA. In the 
later cycles of a PCR reaction, where [DNA] > [Taq], not 
all strands are completed. This is highlighted by addi-
tion of a 10 min step at the end of the reaction. During 
these later cycles, incomplete DNA strands can switch 
templates resulting in the formation of recombinant 
DNA strands, a phenomenon referred to as PCR medi-
ated recombination [5]. This is not detectable when the 
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target is genetically homogenous but is readily seen for 
HIV where there is considerable intra-sample genetic 
heterogeneity [6]. Similarly “DNA shuffling” generates 
large recombinant DNA molecules from smaller DNA 
fragments through template switching [7]. Here strand 
switching occurs by the second round of PCR and larger 
single stranded DNA molecules are built up extend-
ing from the outer primers until they overlap. From that 
point on classical PCR takes over. The amplification HBV 
cccDNA is akin to DNA shuffling.
We wondered whether PCR mediated recombination 
during amplification of the double gapped region of HBV 
rcDNA could generate the target sequence considered to 
be specific for cccDNA.
To test this, three different overlapping HBV frag-
ments simulating the double gapped structure 
of rcDNA were PCR amplified (PCR1 positions 
1545–1818; PCR2 positions 1765–1887; PCR3 posi-
tion 1819–1954; accession number NC_003977.2; 
Fig.  1a). Primers incorporated mutations (underlined) 
to distinguish PCR fragments from input HBVayw 
DNA. Primers were A1sens, 5′GACAGCCC 
GTCTGTGCCTTCTCATGACCCGGA and A2rev, 
5′CATGCAGCTGGTGCGCAGACCAA for PCR1, 
B1sens 5′GGTCTAAGTACTAGGAGGCTGTA and 
B2rev 5′AAGGCTGAGCTTGGAGGCTTGAA for 
PCR2 and C1sens 5′CAACAATTTCACCTCTGCC 
TAAT and C2rev 5′ACGTCAGTAACTCCACAGT 
AGCAGGAAATTCT for PCR3. Amplification condi-
tions were identical for the three fragments and corre-
sponded to 5 min at 95 °C then 30 s at 95 °C, 30 s at 58 °C 
and 2  min at 72  °C for 35 cycles, being completed by a 
final incubation at 72 °C for 10 min. Reactions were per-
formed in a final volume of 100 µl.
The three PCR fragments were purified from aga-
rose gels (Qiaex II kit, Qiagen, France), quantified by 
nanodrop spectrophotometer, mixed on an equimolar 
basis (100 ng final) and subjected to 35 cycles of ampli-
fication with the outer primers A1tsens, 5′GACAG 




































DNA/ng 10 4 1 0.5 0.2 0.04 0.02 PDs
Ct 9.6 12.6 17.7 19.7 22 27.5 28.7 33.7
b M M
123 bp 136 bp
410 bp
274 bp
Fig. 1 Recombinant forms of HBV in vitro and in vivo. a The different open reading frames encoded by the genome, designated as polymerase 
(Pol), core and X are aligned to the three PCR fragments used during the PCR. The HBV polymerase covalently bound to the (−) DNA strand is 
shown by a black circle. Coloured circles represent differences in nucleotides from the input pCayw plasmid (yellow TG‑ > AG and CTG‑ > GAC, orange 
TT‑ > AA; red AC‑ > TG, blue TT‑ > AA, green GT‑ > CA, purple AG‑ > TC and TCC‑ > AGG). b PCR1, PCR2 and PCR3 were amplified under standard con‑
ditions. PCR1 + 2 + 3 represented the 410 bp recombinant forms. M molecular weight markers. c Collection of 164 PCR mediated recombinants. 
The order of the coloured circles distinguishes the different recombinant forms. The number and the frequency of recombinants are presented 
on the left. d Quantification by real‑time PCR based on SYBR Green on serial dilution of the three PCR fragments. All fragments correspond to the 
410 bp fragment. Only primer‑dimers (PDs) were detected in the absence of DNA
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5′ACGTCAGTAACTCCACAGTAGCAGG using 
the above PCR conditions. Primers A1t and C2t cor-
responded to primers A1 and C2 and were shortened 
respectively by 5 and 7 nucleotides 3′ of the primer to 
avoid amplification of HBVayw plasmid. As can be seen 
from Fig.  1b, a 410  bp fragment was readily obtained 
from the mixture of the 123, 136 and 274 bp fragments. 
The 410  bp outer PCR products were cloned using the 
TOPO TA cloning kit (Invitrogen) and individual clones 
sequenced.
As can be seen in Fig. 1c, all of the 164 sequences were 
recombinants where coloured circles represent the muta-
tions introduced into the primers. Thirteen of the sixteen 
possible recombinants were found with frequencies rang-
ing from 0.6 to 23%. The marker mutations, identified by 
colour in Fig. 1a, were present in roughly the same pro-
portions across the 164 sequences consistent with the 
fact that equimolar proportions of each DNA fragment 
were used (orange ~30%, red ~56%, blue ~44% and green 
~48%). Some PCR mediated recombinants required just 
two template switches (one circle) while others required 
six (4 circles, Fig. 1c). The most complex recombinant—
four circles—represented 3.6% of the total. Interestingly, 
no clones with the HBVayw reference sequence were 
found (no circles, Fig.  1a) meaning that there was no 
carry over of input HBV DNA during purification of the 
amplicons.
To determine the sensitivity of the PCR, we performed 
real-time PCR based on SYBR Green with serial dilu-
tions of an equimolar mix of the three PCR fragments. 
Amplification conditions corresponded to 10  min at 
95 °C then 20 s at 95 °C, 20 s at 55 °C and 2 min at 68 °C 
for 40 cycles with primers A1tsens and C2trev. Ampli-
fication was completed by a melting curve step and all 
products were analysed by gel electrophoresis. As can 
be seen from Fig. 1d, 410 bp PCR recombinants could be 
detected down to 20 pg input DNA. While this is a rather 
high threshold, PCR recombination involves the diffusion 
of large molecules many times larger than typical ampli-
fication primers. In addition, a minimum of three cycles 
are necessary to assemble the 410 bp fragment. Hence, a 
rather elevated detection threshold is to be expected.
In order to demonstrate PCR mediated recombina-
tion of bona fide HBV rcDNA, sera from 4 HBV infected 
patients (S1–S4) with high HBV copy numbers (S1 8.42; 
S2 7.28; S3 8.72, S4 7.53 log UI previously described 
[8]) were analysed. Serum can harbour circulating 
genomic DNA and so may contain a little cccDNA from 
necrotized hepatocytes. To investigate this, sera were 
split and part was treated with DNase I (5  units, 2  h, 
37  °C, heat-inactivated at 95  °C, 10  min, Fig.  2a). TP53 
DNA was targeted using primers P53sens 5′GAGC 
TGGACCTTAGGCTCCAGAAAGGACA and P53rev 
5′GCTGGTGTTGTTGGGCAGTGCTAGGAA, PCR 
conditions were described [9] while HBV DNA was 
amplified across the double gap structure using prim-
ers HBVsens 5′GACTCCCCGTCTGTGCCTTCTCA 
and HBVrev 5′ACGAGAGTAACTCCACAGTAGCT. 
TP53 DNA could be recovered from untreated, but not 
DNase I treated sera proving the presence of circulat-
ing chromosomal DNA in all four samples. By contrast 
HBV DNA could be found in both DNase I treated and 
untreated sera (Fig. 2a). Presumably the HBV signal from 
the treated sample comes from rcDNA protected by the 
virion. DNase I treated HBV PCR products were cloned 
and 15–20 clones sequenced from each sample (Fig. 2b). 
Sequences were identical within a serum sample but all 
different between samples proving no cross contamina-
tion between samples. As the virion uniquely contains 
rcDNA, amplification of a 410  bp fragment inevitably 
required PCR mediated recombination.
To investigate sensitivity, we performed real-time 
SYBR Green PCR. Serum S1 (viral load of 8.42 log IU/
ml) was digested with DNase I, serially diluted and the Ct 
determined. There was a good linear correlation between 
log[DNA] and Ct (Fig.  2c) indicating that PCR recom-
binants could be obtained down to the limits of detec-
tion, which is a little lower than 3600 copies. Protocols 
for quantifying cccDNA usually include a treatment by a 
Plasmid-Safe DNase. Accordingly, DNase I treated sera 
S1–S3 were heat inactivated and treated with Plasmid-
Safe DNase (3  units, Illumina) or with T4 Exonuclease 
(3 units, New England BioLabs) for 30 min at 37 °C which 
is typical of such protocols [10]. Target cccDNA was 
quantitated by SYBR Green PCR. As can be observed in 
Fig. 2d, treatment with Plasmid-Safe DNase resulted in a 
higher Ct value indicating that treatment had eliminated 
input DNA. T4 exonuclease treatment eliminated even 
more DNA (Fig.  2d). Despite these treatments, 410  bp 
target cccDNA could be recovered by PCR recombina-
tion, for the input was uniquely rcDNA.
As HBV cccDNA is synonymous with persistent infec-
tion, it is both a therapeutic target and an attractive bio-
marker to follow, while PCR is the obvious technology 
to employ. Distinguishing rcDNA and cccDNA in the 
nucleus is extremely difficult. That the former is found 
in the nucleus is indicated by integrated HBV sequences 
with integration sites mapping close to the 5′ ends of 
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rcDNA strands [11]. From this point on, PCR mediated 
recombination becomes an issue for the identification of 
cccDNA. The use of longer elongation times reduces but 
does not eliminate PCR recombination [5]. Unambiguous 
quantitation of cccDNA by PCR may be more difficult 
than hitherto thought.
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DNase 27.5 29.0 29.2
DNase + PLMD DNase 30.4 30.7 30.9
DNase + T4 exonuclease 31.1 32.3 32.1
Primer-dimers 33.2
b
Fig. 2 Target cccDNA generated from virion associated rcDNA. a PCR analysis of the serum of 4 HBV infected patients (S1–S4) in presence or 
absence of DNase I treatment. TP53 amplification (top) and HBV (bottom). b Sequences of HBV from the serum of the 4 infected patients. The 
sequence from serum 1 was used as reference, the number of sequences analysed is given on the right. Above is a representation of rcDNA for this 
region. c Quantification by real‑time PCR based on SYBR Green on serum S1. d SYBR Green PCR quantification after DNase treatment followed by 
Plasmid‑safe DNase and T4 exonuclease on serum S1, S2 and S3. All amplifications were controlled by gel electrophoresis. Above a Ct of 32.3 only 
primer‑dimers were recovered
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